4.10.19.6Vertical

Spinal Cord Stimulation Programs

Physicians implanting and managing neuromodulation therapy.

Market snapshot

These figures describe Pain Management & Interventional Pain (4.10.19), the segment that Spinal Cord Stimulation Programs sits within — not Spinal Cord Stimulation Programs on its own.

FragmentationConsolidatingEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so pain management is not separately sized.

Business model & economics

Revenue model

Procedure-driven interventional-pain reimbursement

Key economics

Recurring revenue
Moderate

chronic-pain management recurs

EBITDA margin
18–28% with ancillaries
Capex intensity
Moderate

Characteristics

  • Shift toward interventional, non-opioid pain treatment.
  • ASC and neuromodulation ancillaries drive economics.
  • Regulatory sensitivity around opioid prescribing.

M&A deal context

Deal activityModerate

Who’s acquiring

  • PE-backed pain platforms
  • Specialty MSO consolidators
  • ASC-aligned acquirers

What’s driving deals

  • Roll-up for interventional and ASC economics.
  • Chronic-pain and non-opioid-treatment demand.
  • Regulatory scrutiny shaping the specialty.

Find Spinal Cord Stimulation Programs acquisition targets

Search Acquisera’s index for companies classified under Spinal Cord Stimulation Programs (4.10.19.6) and build a targeted deal pipeline.

Search companies